SCHEMBL5757762

SCHEMBL5757762

O=C(Nc1ccc(-c2ccn(CC3CCOCC3)c(=O)c2)c2ccccc12)NC1CC1c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 3/20 0.38
PI4KB Q9UBF8 3/20 0.38
PIK3CG P48736 2/20 0.38
PIK3CD O00329 1/20 0.38
KDM1A O60341 4/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
EPHX2 P34913 4/20 0.38
CNR1 P21554 3/20 0.37
HDAC6 Q9UBN7 1/20 0.37
TRPV1 Q8NER1 2/20 0.35
PIP5K1C O60331 1/20 0.34
CDK9 P50750 1/20 0.34
CNR2 P34972 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
RCOR1 Q9UKL0 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5752633 0.85 PI4KA (0.39) PI4KAPI4KBPIK3CGPIK3CDCNR1
SCHEMBL5753780 0.72 MAPK14 (0.58) KDM1AEPHX2CNR1TRPV1
SCHEMBL28976848 0.70 PI4KA (0.54) PI4KAPI4KBPIK3CGPIK3CDCNR1
SCHEMBL6567627 0.69 CNR1 (0.59) KDM1AEPHX2CNR1TRPV1CA1
SCHEMBL6583540 0.67 MAPK14 (0.61)
SCHEMBL6588782 0.66 EPHX1 (0.38) TRPV1CHRM2CHRM1CHRM3
SCHEMBL5750847 0.66 MAPK14 (0.55) KDM1AHDAC6TRPV1
SCHEMBL5787435 0.65 MAPK14 (0.60) EPHX2CNR2
SCHEMBL13047416 0.64 CCR8 (0.42) CNR1CNR2
SCHEMBL13046748 0.63 P2RX7 (0.42) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414810-B1 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS BOEHRINGER INGELHEIM PHARMA (US) 2006-08-30 EP claimed
US-20030100608-A1 1,4-disubstituted benzo-fused cycloalkyl urea compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-05-29 US claimed
EP-1414810-B1 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS BOEHRINGER INGELHEIM PHARMA (US) 2006-08-30 EP disclosed
US-6720321-B2 REACTING THE ALDEHYDE WITH CARBETHOXYMETHYLENE TRIPHENYLYPHOSPHORANE TO FORM UNSATURATED ESTER, REACTING ESTER WITH DIAZOMETHANE IN PRESENCE OF PALLADIUM ACETATE TO FORM CYCLOPROPANE CABROXYLIC ESTER, HYDROLYSIS TO FORM ACID BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100608-A1 1,4-disubstituted benzo-fused cycloalkyl urea compounds MPO, NFKBIA, YBX1 PI4KA 3023/4885PI4KB 1943/4885PIK3CG 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.